key: cord-0912361-peiqusin
authors: Long, Dustin R; Gombar, Saurabh; Hogan, Catherine A; Greninger, Alexander L; Shah, Vikas O’Reilly; Bryson-Cahn, Chloe; Stevens, Bryan; Rustagi, Arjun; Jerome, Keith R; Kong, Christina S; Zehnder, James; Shah, Nigam H; Weiss, Noel S; Pinsky, Benjamin A; Sunshine, Jacob
title: Occurrence and Timing of Subsequent SARS-CoV-2 RT-PCR Positivity Among Initially Negative Patients
date: 2020-06-07
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa722
sha: cf2373376c42b88f52dc4300cf1408ea29134361
doc_id: 912361
cord_uid: peiqusin

Using data for 20,912 patients from two large academic health systems, we analyzed the frequency of SARS-CoV-2 RT-PCR test-discordance among individuals initially testing negative by nasopharyngeal swab who were retested on clinical grounds within 7 days. The frequency of subsequent positivity within this window was 3.5% and similar across institutions.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the etiologic agent of coronavirus disease 2019 . Accurate detection of the virus is essential to strategies endorsed by the Centers for Disease Control and World Health Organization. As the availability and speed of SARS-CoV-2 testing platforms improve, results of these tests are increasingly relied upon to inform critical decisions related to therapeutic intervention, use of personal protective equipment, patient isolation, and workforce readiness. While the analytic performance of SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) tests are well described [1] , clinical performance is impacted by several factors that are difficult to measure, such as low levels of shedding during incubation and early infection [2] , variability in the site of specimen acquisition [3, 4] , and sufficiency of sample collected. In addition, early reports and characterizations in the press have left the medical community and general public with concerns about the reliability of SARS-CoV-2 RT-PCR testing and the interpretation of negative results. Data characterizing the scope of false negative results observed in the context of current US testing practices are needed to guide clinical protocols and inform the public, but are lacking.

The initial US introduction of COVID-19 through Washington State [5] followed closely by Northern California [6] , combined with the early availability of SARS-CoV-2 testing in both regions [7, 8] , provides an opportunity to evaluate clinical test performance in a population of repeatedly tested patients. In this study, utilizing data from two independent healthcare systems and analyzed by separate research teams, we report the frequency of discordant SARS-CoV-2 RT-PCR results among individuals who initially tested negative and were subsequently retested within 7 days. 

The UW Virology clinical laboratory serves as the primary testing center for a broad region in the US Pacific Northwest, processing over 60% of all SARS-CoV-2 tests for Washington State during the time period examined. In order to ensure consistency of clinical data and compliance with patient privacy policies, analysis was limited to adult patients having an established affiliation with UW Medicine. Encounters spanning multiple facilities (e.g. outpatient, hospital, and drive-through testing locations) were linked using an unambiguous identifier common to all sites. UW guidelines over the study period for testing included the following: all patients who exhibited one or more symptoms of COVID-19 at the time of initial testing per institutional protocol, which involved new symptoms of acute respiratory infection (e.g., fever, cough, shortness of breath, myalgias, rhinorrhea, sore throat, Figure 1A) . Characteristics of initially negative patients are shown in Supplemental Table   1 . The majority of these patients (95.9% UW, 97.4% Stanford) did not undergo repeat testing within 7 days and did not require subsequent evaluation in the form of outpatient, emergency department, or inpatient encounters (Supplemental Table 1 ). Several negatively retested patients at both sites were ultimately diagnosed with other viral respiratory illnesses, most commonly influenza A, rhinovirus, RSV, metapneumovirus, and seasonal coronavirus (Supplemental Table 1 ). However, a small proportion (4.1% UW, 2.6% Stanford) underwent repeat testing within this window despite an initial negative result (Figure 1A) . Among those requiring reevaluation, 96.5% (95.9% UW, 97.2% Stanford) remained negative on all repeat tests performed within 7 days.

It was observed that 3.5% (4.1% UW, 2.8% Stanford) of patients subjected to retesting on clinical grounds within 7 days were subsequently found to be positive during this period, suggesting a false negative initial result. The timing of clinical retesting and occurrence of newly discordant positive results among these patients is shown by site in Figure 1B At UW, the use of standardized testing algorithms enabled subgroup analysis based on testing indication ( Figure 1A) . A total of 299 asymptomatic individuals who were tested as part of universal A c c e p t e d M a n u s c r i p t screening for preoperative clearance were excluded, leaving 7,846 symptomatic individuals who tested negative at the time of initial presentation for analysis. Of the 302 individuals in this group with persistent or worsening symptoms warranting additional testing within 7 days, 4.3% converted from negative to positive and 95.7% remained negative on all subsequent SARS-CoV-2 tests performed within this window.

In this report, two independent research teams describe that, among patients initially testing negative by SARS-CoV-2 RT-PCR of NP swabs, repeat testing within 7 days yielded a positive result in 3.5% of cases; the majority (96.5%) of those warranting additional testing for any reason remained negative on all subsequent tests within this window. Among the subgroup of UW patients confirmed to have symptoms prior to an initial negative result who were retested for persistent or worsening symptoms, a similar proportion (4.3%) were subsequently found to be positive within 7 days. These observations suggest that false negative NP SARS-CoV-2 RT-PCR results do occur, but potentially at a lower frequency than is currently believed.

Results from each research group have limitations. Neither team is able to calculate a true clinical sensitivity or false negative proportion due to the absence of retesting in all initially negative patients and the lack of a gold standard confirmatory mechanism. The cause of false negative initial results also cannot be determined with confidence. However, the range of Ct values observed in subsequent positive assays suggests that both sampling inefficiencies and low viral load (in cases of adequate sampling) may be contributing factors in this population. Additionally, it cannot be ruled out that some discordant test results in this cohort may be due to newly acquired infection. By limiting the scope of retesting considered to a 7-day period, the likelihood of this scenario is minimized, but not eliminated. Finally, we were unable to ascertain the disease status of the individuals who initially tested negative for COVID-19 but did not undergo repeat testing; in most cases this likely reflects the A c c e p t e d M a n u s c r i p t absence of an indication for retesting (e.g. alternative diagnosis or resolution of symptoms), but could also be the result of limited access to care.

The intention of this report is not to definitively quantify the clinical performance of NP SARS-CoV-2 RT-PCR testing, which will likely require orthogonal approaches such as serology. Rather, by characterizing the experience of two large US health systems on the short-term occurrence of newly positive SARS-CoV-2 results among initially test-negative patients, we provide data on a topic of practical significance that should be used in combination with other reports to guide the use and interpretation of this common testing modality.

A c c e p t e d M a n u s c r i p t

COVID-19) EUA Information: In Vitro Diagnostic Products

Virological assessment of hospitalized patients with COVID-2019

Accessed 3

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR

First Case of 2019 Novel Coronavirus in the United States

Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2

Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit

CoV-2 test EUA Summary

We would like to thank Christine Fong and the Center for Perioperative & Pain initiatives in Quality Safety Outcome (PPiQSO) at the University of Washington, Seattle for assistance with the data extract analyzed in the present work. 

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 9.Lu X, Wang A c c e p t e d M a n u s c r i p t Figure 1